Related Experiment Video
Updated: Apr 9, 2026

07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
14.0K
The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC)
Fred Saad1, Kim N Chi2, Antonio Finelli3
1Centre Hospitalier de l'Université de Montréal, Montréal, QC;
Abstract:
Agents that have shown improvements in survival in mCRPC now include abiraterone, enzalutamide, docetaxel, cabazitaxel and radium-223. Bone supportive agents and palliative radiation continue to play an important role in the overall management of mCRPC. Given the complexity, variety and importance of optimizing the use of these agents, a multidisciplinary team approach is highly recommended.

